Twitter help! In line with my previous tweet, what private companies do you know that are testing drugs to evaluate their effect on the lifespan of animals? Testing might include large screenings, lifespan assays, work as CRO, preclinical studies, clinical trials. Please retweet!

. Peter Kolchinsky’s The Great American Drug Deal is a must read

Why do we tell ourselves aging is good, when it is clearly bad? Can we decouple our increase in wisdom from disheartening diagnoses? Why have we made so little progress on improving how we age?🧵 For months, I worked on this piece for PALLADIUM Magazine. It’s about the comforting

Why has menopause become a normal part of every woman's life, when it causes unnecessary suffering? Why is reproductive aging research still significantly underfunded when half of the population experiences menopause? I believe this *needs* to change, so I wrote a piece about

Amaranth retreat = done ✅. Spent the last 48 hours with an incredible team planning out some insane longevity moonshots for the coming year. Watch this space y’all! James Fickel 🪷 Alex Colville Raiany Romanni Joanne Peng

Come join us on March 7th at King's College, Cambridge Cambridge University to hear more about Prof. Kouzarides and his career!

Small molecule and cell contact-inducible systems for controlling expression and differentiation in stem cells ift.tt/5DfaRGQ #biorxiv_synbio

The northern lights have made an appearance in the UK!

In NYC between 17-20th July! Down to grab coffee/lunch/dinner and discuss science! 🧬

🚨 Interested in precise, multi-kilobase scale insertions into the genome? Check out our detailed protocol describing PASTE, out in Nature Protocols ⬇️ nature.com/articles/s4159…

Harvard scientists are leaving academia for the private sector to fast-track biomedical breakthroughs. Michael Mina (eMed), Douglas Melton (Vertex), Stuart Schreiber (Arena Bioworks) cite funding delays & admin hurdles as key reasons. #BiomedicalResearch harvardmagazine.com/2025/01/harvar…

Building on the growing success of the Cold Spring Harbor Laboratory meeting on 3D models and human brain development, I’m thrilled to announce an exciting new conference this December 2025: Assembloids and Complex Cell-Cell Interactions across Tissues and Organs. It’s an honor to co-organize this

Most synthetic biology efforts focus on individual cells. A biosensor, for instance, is typically built inside a single cell. That engineered cell is then "propagated" to form a clonal population, with each cell working in relative isolation. But this paper shows how communities

Super excited to share our recent work now out in nature! We introduce trans-synaptic tracing tools from circuit neuroscience to study the whole-brain connectome of glioblastoma. nature.com/articles/s4158…

Turning 32 (next week), but the lab decided to celebrate early… never thought I’d see my Google Scholar on a cake 😂

Huge congratulations to first authors Chris Fell, Lukas Villiger, Justin Lim and Masahiro Hiraizumi on this work! This paper has been a long time coming! 👏

Precise DNA integration is key for many therapies, but inserting large, scarless sequences remains challenging. What if we could reprogram nature's mobile elements for programmable genome writing? Today we (+ Omar Abudayyeh) debut Stitchr in nature

Super proud to have been a part of this work and thankful for the valuable mentorship of Jonathan Gootenberg and Omar Abudayyeh 👏🏻

1/ The UK feels like a fully coiled spring, ready to unleash. It’s home to many of the finest technical minds on the planet, with 4 of the world’s top 10 research universities. But when it comes to turning science into world-changing startups, it’s lagging.